Agenus drug combo shows 33% three-year survival in colorectal cancer

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. RNG
2. DECK
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. TSCO
9. BE
10. SPY

Go back to Agenus drug combo shows 33% three-year survival in colorectal cancer

Agenus Announces Peer-Reviewed Publication Linking BOT+BAL’s Durable Survival in MSS Metastatic Colorectal Cancer to Its Distinct Immune-Priming Mechanism

August 28, 2026 10:07 AM EDT

Mature 123 patient analysis reports 21.2-month median overall survival and 33% three-year overall survival in heavily pretreated MSS mCRC without active liver metastases Responses observed in tumors with low tumor mutational burden and no PD-L1 expression, reinforcing BOTs Fc-enhanced immune priming mechanism in immunologically cold tumors Durable clinical activity and biomarker findings add biological rationale for evaluating BOT+BAL earlier in the disease course, including curative-intent neoadjuvant colon cancer

LEXINGTON, Mass.--(BUSINESS... More